NUTX
Nutex Health, Inc.
NUTX has the edge over NVO overall, supported by stronger modeled upside and stronger valuation.
NVO
Novo Nordisk A/S
NVO has lower modeled downside risk, despite its lower overall score.
NUTX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Strong | |
| Strong | |
| Strong |
NUTX's profitability, cash flow and balance sheet are currently strong, but its revenue is under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NUTX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 6.4x | $171 | — |
| Current | 7.2x | $171 | — |
| Cheap | 7.3x | $174 | +1.7% |
| Fair | 8.7x | $208 | +21% |
| Expensive | 11x | $255 | +49% |
Historical ranges are pointers, not guarantees.
NUTX's PE is in its cheap range at 7.2x. If earnings grow as analysts expect, today's price would be 6.4x next year's earnings.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO has the edge over NUTX in the historical PE scenario, which offers more potential upside but is not a forecast.
NUTX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Stable | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect NUTX's earnings to grow and its profitability to improve, with its revenue holding steady.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
NUTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $26.68 | +11% |
| Q3 2026 | $23.95 | +24% |
| Q2 2026 | $26.00 | +166% |
| Q1 2026 | $13.67 | +8% |
| Q4 2025 | $10.48 | +14% |
| Q3 2025 | $19.26 | +$28.65 |
| Q2 2025 | $9.78 | +$18.95 |
| Q1 2025 | $12.66 | +$23.26 |
| Q4 2024 | $9.23 | +$21.23 |
NUTX's earnings per share have climbed steadily: $23.95 over the past year, up 24% from the year before, and higher year over year for eight quarters in a row.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
NUTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $217.6M | -19% |
| Q2 2026 | $210.8M | -14% |
| Q1 2026 | $216.5M | +2.2% |
| Q4 2025 | $151.7M | -41% |
| Q3 2025 | $267.8M | +240% |
| Q2 2025 | $244M | +221% |
| Q1 2025 | $211.8M | +214% |
| Q4 2024 | $257.6M | +270% |
NUTX's revenue has slid since its 2025 peak: $218M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | -13 points |
| Q2 2026 | 58% | +44 points |
| Q1 2026 | 38% | -0.6 points |
| Q4 2025 | 20% | -24 points |
| Q3 2025 | 49% | +36 points |
| Q2 2025 | 14% | +6.8 points |
| Q1 2025 | 38% | +36 points |
| Q4 2024 | 44% | +82 points |
NUTX has the edge over NVO on profitability, with a higher operating margin.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO's operating margin was 34% last quarter, down 9 points from the same quarter a year ago, near the bottom of its range since 2019.
NUTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $73.1M | -26% |
| Q2 2026 | $31.7M | +19% |
| Q1 2026 | $74.3M | +46% |
| Q4 2025 | $69M | +$69.3M |
| Q3 2025 | $99.2M | +1507% |
| Q2 2025 | $26.5M | +109% |
| Q1 2025 | $50.9M | +2096% |
| Q4 2024 | -$341.8K | +$608.8K |
NUTX has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
NUTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +20.7K shares |
| 1 year | -1.9% | -136K shares |
| 3 years | +59% | +2.6M shares |
NUTX has the edge over NVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $1,000 |
| Q2 2026 | $19M |
| Q1 2026 | $31.7M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
NUTX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.6x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.6x | Net Cash |
| Q4 2025 | -0.5x | Net Cash |
| Q3 2025 | -0.3x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.2x | Net Cash |
| Q4 2024 | -0.0x | Net Cash |
NUTX has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
NUTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.5 | Neutral |
| Stochastic | 42.9 | Neutral |
NUTX's weekly RSI is 48 (neutral) and its Stochastic is 43 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
NUTX PE vs Healthcare Sector
| Metric | NUTX | Sector median | Relative |
|---|---|---|---|
| PE | 7.2x | 26x | 72% below |
| PE % | 13 | 29 | 16 pts below |
NUTX has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
NUTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $198.8 | 14% below |
| 20 week MA | $187.7 | 8.7% below |
| 50 week MA | $153.5 | 12% above |
| 100 week MA | $123.4 | 39% above |
| 200 week MA | $86.9 | 97% above |
NUTX has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
NUTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $301.5 | $157.5 | -48% |
| 2021 | $157.5 | $619.5 | +293% |
| 2022 | $619.5 | $312.0 | -50% |
| 2023 | $312.0 | $27.0 | -91% |
| 2024 | $27.0 | $31.9 | +18% |
| 2025 | $31.9 | $176.7 | +455% |
| 2026 YTD | $176.7 | $171.4 | -3% |
NUTX has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.